Mural Oncology (NASDAQ:MURA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05), RTT News reports. During the same quarter in the prior year, the company posted ($3.57) EPS.
Mural Oncology Price Performance
Shares of MURA opened at $3.73 on Thursday. Mural Oncology has a one year low of $2.87 and a one year high of $5.38. The company has a 50-day moving average of $3.84 and a two-hundred day moving average of $3.58. The stock has a market cap of $63.48 million, a price-to-earnings ratio of -0.41 and a beta of 3.66.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Wednesday.
About Mural Oncology
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
- Five stocks we like better than Mural Oncology
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount?
- CD Calculator: Certificate of Deposit Calculator
- 3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?
- What is the Euro STOXX 50 Index?
- 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
